Mylan NV (MYL) was Upgraded by Raymond James to ” Strong Buy”. Earlier the firm had a rating of “Mkt Perform ” on the company shares. Raymond James advised their investors in a research report released on Oct 10, 2016.
Many Wall Street Analysts have commented on Mylan NV. Shares were Reiterated by RBC Capital Mkts on Sep 6, 2016 to “Sector Perform” and Lowered the Price Target to $ 48 from a previous price target of $52 .
On the company’s financial health, Mylan NV reported $1.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $1.13. The company had revenue of $2560.70 million for the quarter, compared to analysts expectations of $2572.65 million. The company’s revenue was up 8.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Mylan NV closed down -0.9 points or -2.44% at $35.94 with 1,08,71,234 shares getting traded on Friday. Post opening the session at $36.81, the shares hit an intraday low of $35.58 and an intraday high of $36.84 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Aug 11, 2016, Heather M Bresch (Chief Executive Officer) sold 100,200 shares at $50.00 per share price. According to the SEC, on Jun 6, 2016, Joseph C Md Maroon (director) purchased 1,670 shares at $44.95 per share price. On May 25, 2016, Robert J Cindrich (director) purchased 1,190 shares at $42.47 per share price, according to the Form-4 filing with the securities and exchange commission.
Mylan N.V. formerly Mylan Inc. is a global pharmaceutical company which develops licenses manufactures markets and distributes generic branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively North America); Europe the Middle East and Africa (collectively EMEA); and India Australia Japan and New Zealand (collectively Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India) which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.